Pricing the Next Wave of COPD Therapies: Lessons from Current Reimbursement Patterns
Read More
June 2026
Value-Informed Launch Price Estimates for Disease-Modifying Therapies for RRMS
Substantial value is created from delaying progression and reducing relapses.
In this Center for Pharmacoeconomics Exclusive, we calculated value-informed launch price estimates for a disease-modifying therapy for relapsing-remitting multiple sclerosis. These price estimates ranged from tens of thousands of dollars annually under conservative health system–only frameworks to several hundred thousand dollars annually when broader societal value elements and higher willingness-to-pay thresholds were considered.
Key takeaways:
- Value-informed price estimates vary substantially across frameworks and thresholds. The estimates can vary widely depending on treatment effectiveness, cost-effectiveness framework, and the value elements considered, highlighting how clinical performance and economic assumptions can defend pricing.
- Treatment effectiveness is a primary driver of economic value. Greater reductions in disability progression and relapse rates substantially increase value-informed price estimates, underscoring the potential influence of clinical performance on pricing conversations.
- Including societal value elements meaningfully increases estimated value. Accounting for impacts beyond the healthcare system (e.g., patient productivity gains and reductions in caregiver time) can substantially increase value-informed price estimates compared with analyses limited to health system costs.
- Modeling long-term drug pricing dynamics affects estimated value. Incorporating expected price reductions following loss of exclusivity and generic entry provides a more realistic representation of long-term treatment costs for a chronic condition such as RRMS, where patients may remain on therapy for decades.
- Implications for biotech companies and investors. Understanding how clinical outcomes translate into value-based price estimates can help contextualize the potential economic value of pipeline therapies, guide evidence generation, and inform pricing acceptance in an environment of increasing pricing scrutiny.
For details on obtaining full access to the report, contact us via email at cpe@medacorp.com.
The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners
Leerink Center for Pharmacoeconomics
– Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
